Skip to content
lifestyle.tvshowauditions.info
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Inhibrx Biosciences, Inc.
Inhibrx Reports Third Quarter 2026 Financial Results
November 13, 2026
Inhibrx Announces Participation in Upcoming Scientific Conferences
October 13, 2026
INBRX-106 Trial Shows Near Double Response Rate in HNSCC
September 8, 2026
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
September 4, 2026
Inhibrx Reports Second Quarter 2026 Financial Results
August 13, 2026
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
June 15, 2026